-
The clinical implications of the microbiome in the development of allergy diseases Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2021-01-11 Larissa Koidl; Eva Untersmayr
Abstract Introduction A substantial number of patients worldwide is affected by allergies. Emerging evidence suggests that the individual microbial composition might contribute to the development of allergies or might even protect from allergic diseases. Areas covered This review provides a detailed summary regarding available knowledge on the composition of a healthy human microbiome at allergy relevant
-
Genomic and transcriptional changes in IFNγ pathway genes are putative biomarkers of response to ipilimumab immunotherapy in melanoma patients Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-15 Kristian M. Hargadon; Balázs Győrffy; Taylor J. McGee
ABSTRACT Evaluation of: Gao J, Shi LZ, Zhao H et al. Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy. Cell 167(2), 397–404 (2016). Tumor resistance to immune checkpoint inhibitors limits therapeutic efficacy in many cancer patients. The study by Gao et al. highlighted herein describes a fundamental mechanism by which melanoma escapes the CTLA-4-targeting
-
Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-16 George E. Fragoulis; Dimitris Daoussis; Eleni Pagkopoulou; Alexandros Garyfallos; George D. Kitas; Theodoros Dimitroulas
ABSTRACT Introduction: Systemic sclerosis (SSc) is associated with a heightened cancer risk compared to the general population. Several pathways including immune system upregulation, cumulative inflammation, environmental factors, and genetic predisposition contribute to the development of both cancer and autoimmunity. Areas covered: This paper provides an overview of studies investigating the relationship
-
Chronic rhinosinusitis with nasal polyps: mechanistic insights from targeting IL-4 and IL-13 via IL-4Rα inhibition with dupilumab Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-15 Harsha H Kariyawasam
ABSTRACT Introduction: Chronic rhinosinusitis with nasal polyps (CRSwNP) is a complex immunological upper airway disease . CRSwNP, particularly in Caucasians, often has a more distinct T2 inflammatory endotype. IL-4 and IL-13 are key upstream cytokines that help establish and sustain T2 inflammation as well as strongly influencing tissue remodeling. They have a shared signaling receptor IL-4Rα. An
-
Myosin light chain kinase regulates intestinal permeability of mucosal homeostasis in Crohn’s disease Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-29 Yiran Yao; Qi Feng; Jun Shen
ABSTRACT Introduction: Researchers have investigated the potential role of intestinal permeability in Crohn’s disease pathogenesis. Intestinal permeability is usually mediated by cytoskeleton and intercellular junctions. The myosin light chain kinase (MLCK) is an enzyme that activates the myosin light chain to exert its function related to cytoskeleton contraction and tight junction regulation. The
-
The role of Epstein-Barr virus in the etiology of multiple sclerosis: a current review Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-17 Klemens Ruprecht
ABSTRACT Introduction: Multiple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system. While its exact etiology is unknown, it is generally believed that MS is caused by environmental triggers in genetically predisposed individuals. Strong and consistent evidence suggests a key role of Epstein-Barr virus (EBV), a B lymphotropic human gammaherpesvirus, in the etiology
-
Natural history of COVID-19 and therapeutic options Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-24 Philippe Gautret; Matthieu Million; Pierre-André Jarrot; Laurence Camoin-Jau; Philippe Colson; Florence Fenollar; Marc Leone; Bernard La Scola; Christian Devaux; Jean Yves Gaubert; Jean-Louis Mege; Joana Vitte; Cléa Melenotte; Jean-Marc Rolain; Philippe Parola; Jean-Christophe Lagier; Philippe Brouqui; Didier Raoult
ABSTRACT Introduction: COVID-19 presents benign forms in young patients who frequently present with anosmia. Infants are rarely infected, while severe forms occur in patients over 65 years of age with comorbidities, including hypertension and diabetes. Lymphopenia, eosinopenia, thrombopenia, increased lactate dehydrogenase, troponin, C-reactive protein, D-dimers and low zinc levels are associated with
-
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-25 Isabelle Amigues; Alexander H Pearlman; Aarat Patel; Pankti Reid; Philip C. Robinson; Rashmi Sinha; Alfred Hj Kim; Taryn Youngstein; Arundathi Jayatilleke; Maximilian Konig
ABSTRACT Introduction: The mortality of coronavirus disease 2019 (COVID-19) is frequently driven by an injurious immune response characterized by the development of acute respiratory distress syndrome (ARDS), endotheliitis, coagulopathy, and multi-organ failure. This spectrum of hyperinflammation in COVID-19 is commonly referred to as cytokine storm syndrome (CSS). Areas covered: Medline and Google
-
The wide spectrum of Kawasaki-like disease associated with SARS-CoV-2 infection Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-25 Onorina Berardicurti; Alessandro Conforti; Piero Ruscitti; Paola Cipriani; Roberto Giacomelli
ABSTRACT Introduction: On June 2020, the first case of concurrent Covid-19 and Kawasaki disease (KD) was published. After this first description, further works reported new cases of children affected by KD and KD-like syndrome after SARS-CoV-2 infection. The clinical and biochemical features of these patients differed from the historical cohorts of KD, suggesting the possibility of a new multi-systemic
-
FIRST LINE OF SUBCUTANEOUS ANTI-TNF THERAPY FOR RHEUMATOID ARTHRITIS: A PROSPECTIVE COHORT STUDY Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-15 Jéssica Barreto Ribeiro Dos Santos; Michael Ruberson Ribeiro da Silva; Adriana Maria Kakehasi; Franciscode Assis Acurcio; Alessandra Maciel Almeida; Haliton Alves de Oliveira Junior; Pedro Ricardo Kömel Pimenta; Juliana Alvares-Teodoro
ABSTRACT Objectives: This study aims to evaluate and compare the use of subcutaneous anti-TNF for RA in a Brazilian real-life setting. Methods: A prospective cohort of biological disease-modifying antirheumatic drug (bDMARD)-naïve patients treated with adalimumab, etanercept, golimumab, and certolizumab was developed. Medication persistence, disease activity by the Clinical Disease Activity Index (CDAI)
-
Autoimmunity in common variable immunodeficiency: a systematic review and meta-analysis Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-07 Fatema Sadaat Rizvi; Hamed Zainaldain; Hosein Rafiemanesh; Mahnaz Jamee; Nikoo Hossein-Khannazer; Haleh Hamedifar; Araz Sabzevari; Reza Yazdani; Hassan Abolhassani; Asghar Aghamohammadi; Gholamreza Azizi
ABSTRACT Objectives: Common variable immunodeficiency (CVID) is the most common symptomatic inborn error of immunity characterized by variable clinical manifestations. Methods: Web of Science, Scopus, and PubMed databases were searched systemically to find eligible studies from the earliest available date to February 2020 with standard keywords. Pooled estimates of the autoimmunity prevalence and the
-
Clinical management of patients with primary immunodeficiencies during the COVID-19 pandemic Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2021-01-07 Isabella Quinti; Ivano Mezzaroma; Cinzia Milito
Abstract Introduction: Patients affected by Inborn Errors of Immunity (IEI) represent a potential group-at-risk in the current COVID-19 pandemic. Studies on large and small cohorts of IEI reported a huge variability clinical manifestations associated to SARS-Cov-2, ranging from asymptomatic, mild, moderate/severe to death. A great impulse to improve remote assistance programs and to switch to home-based
-
Predicting lupus flares: epidemiological and disease related risk factors Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2021-01-04 Samuel Andrade; Paulo Rogerio Julio; Diego Nunes de Paula Ferreira; Appenzeller Simone
Abstract Introduction: Systemic lupus erythematosus (SLE) is a chronic autoimmune disorder, characterized by a relapsing and remitting pattern of disease activity in majority of the patients. Areas covered: This narrative review provides an overview of flare definition, major flare mimics and the burden of flares in SLE. The authors highlight epidemiology and disease-related risk factor for flares
-
The importance of transition from pediatric to adult rheumatology care in juvenile idiopathic arthritis Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2021-01-04 Rodrigo Joel de Oliveira; Simone Thiemi Kishimoto; Débora Pessoa de Souza; Paula Teixeira Fernandes; Roberto Marini; Appenzeller Simone
Abstract Introduction Juvenile idiopathic arthritis (JIA) is the most common rheumatic inflammatory condition in childhood. The long-term morbidity, mortality and quality of life has improved with the earlier use of disease modifying drugs (DMARDs) and the availability of biology disease modifying drugs (bDMARDs). Despite improvement of treatment, around 50% of patients reach adulthood with articular
-
Cardiac involvement in the adult primary vasculitides. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-24 Giulia Pazzola,Nicolò Pipitone,Carlo Salvarani
ABSTRACT Introduction Heart involvement in vasculitis is rare, but potentially severe. The ascertainment of cardiac disease in vasculitis is complex and requires an integrated multidisciplinary approach involving the Rheumatologist, Radiologist, Cardiologist, and Heart surgeon. Areas covered the authors searched PubMed using the keywords ‘heart’[Mesh] and vasculitis”[Mesh]. Expert opinion Virtually
-
Chimeric antigen receptor T cell therapy for pediatric and young adult B cell acute lymphoblastic leukemia. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-30 Regina M Myers,Joseph G Dolan,David T Teachey
ABSTRACT Introduction Though 85% of children and young adults with acute lymphoblastic leukemia (ALL) are cured, until recently, the prognosis of relapsed or refractory disease has been dismal. The advent of chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of relapsed/refractory ALL. The most well-studied, successful CARs are autologous, murine-based anti-CD19 CARs, but
-
5-Aza-2’-deoxycytidine enhanced the frequency of T Regulatory Cells from CD4+ naïve T cells isolated from the peripheral blood of patients with chronic HBV infection Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-23 Yu Fang; Xiao-Dong Yuan; Hui-Hui Liu; Lin Xiang; La-Mei Chen; Yu-Chen Fan; Shuai Gao; Kai Wang
Abstract Objectives Methylation pattern of gene modification is essential for the differentiation of T regulatory cells (Tregs) and 5-Aza-2ʹ-deoxycytidine is a common inhibitor of methylation. This study aimed to investigate the potential effects of Treg polarizing conditions and 5-Aza-2ʹ-deoxycytidine treatment in the differentiation of naïve T cells during chronic hepatitis B virus (HBV) infection
-
Efficacy and safety of subcutaneous infliximab versus adalimumab, etanercept and intravenous infliximab in patients with rheumatoid arthritis: a systematic literature review and meta-analysis Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-11 Roberto Caporali; Yannick Allanore; Rieke Alten; Bernard Combe; Patrick Durez; Florenzo Iannone; Mike T. Nurmohamed; Sang Joon Lee; Taek Sang Kwon; Jean Soo Choi; Gahee Park; Dae Hyun Yoo
Abstract Objectives There are few comparative data for tumor necrosis factor inhibitors in patients with rheumatoid arthritis (RA). Methods Historical data for reference product/biosimilar intravenous infliximab, or adalimumab and etanercept, were pooled and compared with phase 3 study results for a subcutaneous (SC) formulation of the infliximab biosimilar CT-P13, in a systematic review and meta-analysis
-
Reply to “Taking a stand against the politicization of medical research: How ‘winging the pendulum’ poses a hazard to clinical trials, study participants, and the progress of science” Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-08 Sebastian E. Sattui; Elizabeth R. Graef; Jean W. Liew; Jeffrey A. Sparks; Alfred H.J Kim
Reply to “Taking a stand against the politicization of medical research: How ‘winging the pendulum’ poses a hazard to clinical trials, study participants, and the progress of science”. Expert Review of Clinical Immunology. Accepted 4 December 2020.
-
Taking a stand against the politicization of medical research: How “swinging the pendulum” poses a hazard to clinical trials, study participants, and the progress of science. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-07 Anna Bershteyn; Mark D. Schwartz; Lorna E. Thorpe; Michael K. Paasche-Orlow; Patricia Kissinger; Helen C. Stankiewicz Karita; Miriam K. Laufer; Risa M. Hoffman; Raphael J. Landovitz; Kristopher Paolino; Ruanne V. Barnabas
Taking a stand against the politicization of medical research: How “swinging the pendulum” poses a hazard to clinical trials, study participants, and the progress of science.. Expert Review of Clinical Immunology. Accepted 4 December 2020.
-
Immunological mechanisms underlying sterile inflammation in the pathogenesis of atherosclerosis: potential sites for intervention Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-05 Roland Truong; Finosh G. Thankam; Devendra K Agrawal
Abstract Introduction: Innate and adaptive immunity play a critical role in the underlying pathological mechanisms of atherosclerosis and potential target sites of sterile inflammation open opportunities to develop novel therapeutics. In response to oxidized LDL in the intimal layer, T cell subsets are recruited and activated at the site of atheroma to upregulate pro-atherogenic cytokines which exacerbate
-
The emerging role of Type 2 inflammation in asthma Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-05 Matucci Andrea; Bormioli Susanna; Nencini Francesca; Maggi Enrico; Vultaggio Alessandra
Abstract Introduction: Bronchial asthma (BA) is a chronic airways inflammatory disease characterized by an influx of cells such as lymphocytes, eosinophils, and mast cells. Based on the biological mechanisms that underline the disease, asthma has been classified as type 2 or non-type 2 phenotype. Th2 lymphocytes are able to release interleukin (IL)-4, IL-5, IL-9, and IL-13 that are the main factors
-
Therapeutic targeting of the IL-13 pathway in skin inflammation Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-04 Carla Tubau; Lluís Puig
Abstract Introduction: Atopic dermatitis (AD) is a heterogeneous, chronic, inflammatory skin disease with a non-negligible prevalence at present. Its pathogenesis is complex, but mainly characterized by constitutive T helper type 2 (Th2)-cell activation. Systemic therapies for moderate-to-severe AD can be associated with adverse events that encumber their satisfactory long-term use. Several drugs targeting
-
“Real-world” effectiveness of omalizumab in adults with severe allergic asthma: a meta-analysis Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-01 Kenneth M. Faulkner; Karen MacDonald; Ivo Abraham; Abdulaziz Alhossan; Christopher S. Lee
Abstract Background : Severe asthma affects approximately 5-10% of the 350 million people with asthma worldwide and is characterized by persistent symptoms in spite of optimal treatment. Findings from the authors’ previous meta-analysis supported the use of omalizumab, a monoclonal antibody, as adjuvant treatment for severe allergic asthma. The publication of nine additional articles necessitates an
-
Diagnosis and treatment of non-allergic rhinitis: focus on immunologic mechanisms Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-12-01 Yifan Meng; Chengshuo Wang; Luo Zhang
Abstract Introduction Non-allergic rhinitis (NAR) is a heterogeneous nasal disease with high global prevalence. NAR can be subclassified as nonallergic rhinitis with eosinophilia syndrome (NARES), vasomotor rhinitis (VMR), and local allergic rhinitis (LAR). Although the precise factors involved in the etiology of NAR are not clear, there is evidence that immunological factors play an important role
-
Guselkumab: the first selective IL-23 inhibitor for active psoriatic arthritis in adults Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-28 Wolf-Henning Boehncke; Nicolo Costantino Brembilla; Michael John Nissen
Abstract Introduction Guselkumab is a subcutaneously administered human monoclonal antibody, selectively blocking IL-23 through binding to its p19 subunit. It was initially approved for the treatment of patients with moderate-to-severe plaque-psoriasis who are candidates for systemic therapy or phototherapy. Pubmed and Embase databases were searched for publications, using the following search terms:
-
Ataxia-telangiectasia: Epidemiology, Pathogenesis, Clinical Phenotype, Diagnosis, Prognosis and Management. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-15 Parisa Amirifar,Mohammad Reza Ranjouri,Martin Lavin,Hassan Abolhassani,Reza Yazdani,Asghar Aghamohammadi
ABSTRACT Introduction Ataxia-telangiectasia (A-T) is a rare autosomal recessive syndrome characterized by progressive cerebellar ataxia, oculocutaneous telangiectasia, variable immunodeficiency, radiosensitivity, and cancer predisposition. Mutations cause A-T in the ataxia telangiectasia mutated (ATM) gene encoding a serine/threonine-protein kinase. Areas covered The authors reviewed the literature
-
Diagnosis and management of hypersensitivity reactions to vaccines. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-09-29 Lucrezia Sarti,Guillaume Lezmi,Francesca Mori,Mattia Giovannini,Jean-Christoph Caubet
ABSTRACT Introduction Many countries in Europe now recommend and enforce mandatory vaccinations to improve vaccination coverage. Thus, the number of adverse events following immunization (AEFI) may show an increase. Among these events, severe hypersensitivity reactions to vaccines are rare. However, it is important that they be identified and recognized so that they may be adequately managed. Areas
-
A systematic literature review of the effects of immunoglobulin replacement therapy on the burden of secondary immunodeficiency diseases associated with hematological malignancies and stem cell transplants. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-21 Clara Monleón Bonet,Nathalie Waser,Spiros Tzivelekis,J David M Edgar,Silvia Sánchez-Ramón,Karen Cheng
ABSTRACT Introduction Secondary immunodeficiency diseases (SID) caused by hematological malignancies (HMs), stem cell transplant (SCT), and associated therapies are mainly characterized by the presence of hypogammaglobulinemia or antibody production deficits. Areas covered The authors summarized the scientific literature on disease burden of SIDs in patients who had HMs or SCT. Systematic searches
-
Efficacy and safety of imatinib mesylate in systemic sclerosis. A systematic review and meta-analysis. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-03 Vasiliki Liakouli,Jacopo Ciaffi,Francesco Ursini,Piero Ruscitti,Riccardo Meliconi,Francesco Ciccia,Paola Cipriani,Roberto Giacomelli
ABSTRACT Objectives To synthetize the available evidence concerning efficacy and safety of imatinib mesylate, a tyrosine kinase inhibitor, in systemic sclerosis (SSc). Methods A systematic search following the PRISMA-statement in PubMed/MEDLINE, Cochrane CENTRAL, and Web of Science databases up to 7 February 2020 was conducted. Considering the substantial heterogeneity expected, a random-effects model
-
Association between gene polymorphisms of TGF-β and Smad3 and susceptibility to arthritis: a meta-analysis Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-06 Jianxin Liu; Qing Chen; Erpan Alkam; Xiaolan Zheng; Yifei Li; Lufei Wang; Jie Fang
ABSTRACT Objectives This meta-analysis was performed to investigate the associations between single-nucleotide polymorphisms (SNPs) in the TGF- β and Smad3 genes and arthritis. Methods A meta-analysis was performed in STATA 14.0, with publication bias and meta-regression analysis. All types of arthritis were included, and subgroup analyses were performed to interpret variations among different types
-
Stumbles in Sjögren's syndrome drug development: where to look for the next big leap? Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-16 Gwenny M. Verstappen; Frans G.M. Kroese; Hendrika Bootsma
(2020). Stumbles in Sjögren's syndrome drug development: where to look for the next big leap?. Expert Review of Clinical Immunology. Ahead of Print.
-
Autism Spectrum Disorders and Natural Killer Cells: A Review on Pathogenesis and Treatment Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-11-15 Sepideh Ebrahimi Meimand; Yasna Rostam-Abadi; Nima Rezaei
Abstract Introduction: Autism spectrum disorder (ASD), as a wide spectrum of neurodevelopmental disorders, is characterized by early-onset impairments in social-communication, repetitive behaviors, and restrictive interests. Areas covered: Although still unknown, there are some pieces of evidence suggesting altered immune function in the etiology of ASD. This review aims to summarize studies linking
-
Mechanical ventilation in Guillain–Barré syndrome Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-28 Pei Shang; Mingqin Zhu; Matthew Baker; Jiachun Feng; Chunkui Zhou; Hong-Liang Zhang
Abstract Introduction Up to 30% of patients with Guillain–Barré syndrome (GBS) develop respiratory failure requiring intensive care unit (ICU) admission and mechanical ventilation. Progressive weakness of the respiratory muscles is the leading cause of acute respiratory distress and respiratory failure with hypoxia and hypercarbia. Bulbar weakness may compromise airway patency and predispose patients
-
Gut Microbiota in Celiac Disease: Microbes, Metabolites, Pathways and Therapeutics Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-26 Katherine L Olshan; Maureen M Leonard; Gloria Serena; Ali R Zomorrodi; Alessio Fasano
Abstract Introduction Current evidence supports a vital role of the microbiota on human health outcomes, with alterations in an otherwise healthy balance linked to chronic medical conditions such as celiac disease (CD). Recent advances in microbiome analysis allow for unparalleled profiling of the microbes and metabolites. With the growing volume of data available, trends are emerging that support
-
The power of the EUSTAR cohort: key findings to date and implicationsfor management of systemic sclerosis patients Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-19 Francesco Benvenuti; Elisabetta Zanatta; Jérôme Avouac; Ulf Müller-Ladner; Franco Cozzi; Anna-Maria Hoffmann-Vold; Armando Gabrielli; Oliver Distler; Marco Matucci-Cerinic; Yannick Allanore; Andrea Doria
Abstract Introduction The rarity of systemic sclerosis (SSc) and its widely heterogeneous presentation and disease course are the main limitations for clinical research. The European Scleroderma Trials and Research group (EUSTAR) was launched in 2004, aiming to unify research efforts in the field of SSc. The central EUSTAR database has grown exponentially over the years, promoting new research and
-
Evaluation of different classification criteria in children with Behcet disease: results from a single referral center Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-13 Rabia Miray Kisla Ekinci; Ebru Esen; Ahmet Hakan Erol; Selcuk Sızmaz; Dilek Karagoz; Derya Ufuk Altintas; Sibel Balcı
Abstract Objectives Behcet Disease (BD) is a systemic vasculitis, first described with a triad of oral aphthous ulcers, genital ulcers, and uveitis. The authors aimed to share the clinical properties and utilities of three distinct classification criteria for BD in this study. Methods This case-control study was conducted in pediatric BD patients, diagnosed between January 2012 and July 2019. The control
-
Teprotumumab for the treatment of thyroid eye disease. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-09 Yongjing Ju,Junyi Yang
ABSTRACT Introduction Thyroid eye disease is a debilitating, disfiguring, and potentially blinding periocular condition. Teprotumumab is a human insulin-like growth factor-I receptor monoclonal inhibitor antibody which indicated for treating thyroid eye disease. Areas covered The authors performed a systematic review of the literature using the PubMed database, and the following keywords were used:
-
Ixekizumab for the treatment of ankylosing spondylitis. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-24 Jin-Xian Huang,Yung-Heng Lee,James Cheng-Chung Wei
ABSTRACT Introduction Ixekizumab (IXE) is a high affinity IgG4 approved for the treatment of ankylosing spondylitis (AS). Recently, two phase III randomized clinical trials (COAST-V, COAST-W) showed significant and sustained improvements in signs and symptoms of AS as evaluated by ASAS40 response. Areas covered: The authors performed a comprehensive literature search on this topic, by a review of published
-
Pathogenesis and treatment of idiopathic and rheumatoid arthritis-related interstitial pneumonia. The possible lesson from COVID-19 pneumonia. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-03 A Manfredi,F Luppi,G Cassone,C Vacchi,C Salvarani,M Sebastiani
ABSTRACT Introduction Main clinical manifestations of SARS-CoV-2 infection are characterized by fever, dyspnea, and interstitial pneumonia, frequently evolving in acute respiratory distress syndrome (ARDS). Areas covered Features of coronavirus disease 2019 (COVID-19) presents some common points with interstitial lung disease (ILD) both idiopathic and related to rheumatoid arthritis (RA), typically
-
Immune checkpoint inhibitor-induced inflammatory arthritis: identification and management. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-24 Sandra G Williams,Arash Mollaeian,James D Katz,Sarthak Gupta
ABSTRACT Introduction Immune checkpoint inhibitors (ICIs) have proved to be groundbreaking in the field of oncology. However, immune system overactivation from ICIs has introduced a novel medical entity known as immune-related adverse events (irAEs), that can affect any organ or tissue. ICI-induced inflammatory arthritis (ICI-IIA) is the most common musculoskeletal irAE and can lead to significant
-
Early-life exposure to air pollution and childhood allergic diseases: an update on the link and its implications. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-12 Chan Lu,Dan Norbäck,Yuguo Li,Qihong Deng
ABSTRACT Introduction Although mounting evidence has linked environmental factors with childhood allergies, some specific key issues still remain unclear: what is the main environmental factor? what is the critical timing window? And whether these contribute to the development of disease? Areas covered This selective review summarizes recent epidemiological studies on the association between early-life
-
NEW INSIGHTS INTO THE PROGRESSION FROM CUTANEOUS LUPUS TO SYSTEMIC LUPUS ERYTHEMATOSUS. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-09-29 Wenhui Zhou,Haijing Wu,Ming Zhao,Qianjin Lu
ABSTRACT Introduction Between 5 and 25% of patients with cutaneous lupus erythematosus (CLE) can progress to systemic lupus erythematosus (SLE) during the course of the disease. There is no clear predictive guideline for the progression of CLE to SLE. Areas covered Lupus erythematosus (LE), a chronic autoimmune disease, has a wide spectrum of manifestations. On one side of the spectrum is CLE, in which
-
Current concepts underlying the pathophysiology of acute Charcot neuroarthropathy in the diabetic foot and ankle. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-10 Thomas H Yates,Steven R Cooperman,David Shofler,Devendra K Agrawal
ABSTRACT Introduction With a complex and often misunderstood etiology, acute Charcot neuroarthropathy (ACN) is a devastating complication of peripheral neuropathy. In patients with diabetes, timely diagnosis of ACN in the foot and ankle is essential to prevent loss of both limb and life. Areas covered Herein, the authors evaluate the growing body of evidence in identifying targeted pathways for future
-
Vitamin D: does it help Tregs in active rheumatoid arthritis patients. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-25 Hanaa Samy El-Banna,Souzan Ezzat Gado
ABSTRACT Background Regulatory T cells (Tregs) play an important role in the maintenance of immunological tolerance. Tregs deficiency or suppressor functions reduction may be associated with autoimmune diseases development. Objectives To estimate the effect of vitamin D supplementation on Tregs level in the peripheral blood of active rheumatoid arthritis (RA) patients. Methods 40 active RA patients
-
Thunderstorm asthma: an overview of mechanisms and management strategies. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-12 Francis Thien,Janet M Davies,Mark Hew,Jo A Douglass,Robyn E O'Hehir
ABSTRACT Introduction Epidemic thunderstorm asthma (ETSA) is due to a complex interaction of environmental and individual susceptibility factors, with outbreaks reported globally over the last four decades. Australia has been particularly susceptible with nearly half of episodes reported internationally, culminating in the catastrophic Melbourne 2016 event. Areas covered Reported ETSA episodes are
-
Abrocitinib for the treatment of atopic dermatitis. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-08 Erika L Crowley,Novin Nezamololama,Kim Papp,Melinda J Gooderham
ABSTRACT Introduction Janus kinase (JAK) inhibitors are emerging treatments in dermatology. Also known as JAKinibs, these agents target JAK-signal transducers and activators of transcription (JAK-STAT) pathway for intracellular signaling. Among the various immune-mediated inflammatory skin diseases that the JAK-STAT pathway plays a role in, atopic dermatitis (AD) is an important one. AD has a complex
-
Local Bacteriotherapy – a promising preventive tool in recurrent respiratory infections. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-06 Giorgio Ciprandi; Ignazio La Mantia; Valerio Damiani; Desiderio Passali
Abstract Introduction Children with recurrent respiratory infections (RRI) represent a social issue for the economic burden and the negative family impact. Local Bacteriotherapy is an attractive therapeutic strategy that could be potentially effective in preventing infections. The current article remarks on the existing evidence of preventing RRI by Local Bacteriotherapy. Areas covered The literature
-
Diagnostic and prognostic markers and treatment of connective tissue disease-associated pulmonary arterial hypertension: current recommendations and recent advances Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-05 Masaru Kato; Ayako Sugimoto; Tatsuya Atsumi
ABSTRACT Introduction Pulmonary arterial hypertension (PAH), also referred to as group 1 pulmonary hypertension, occurs either primarily or in association with other diseases such as connective tissue diseases (CTD). Of CTD, systemic sclerosis (SSc), systemic lupus erythematosus and mixed connective tissue disease are commonly accompanied with PAH. It is of note that SSc-PAH is associated with distinctive
-
Multimorbidity and comorbidity in psoriatic arthritis - a perspective. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-10-03 Ennio Lubrano,Silvia Scriffignano,Fabio Massimo Perrotta
ABSTRACT Introduction Psoriatic Arthritis (PsA) is a multifaceted disease in which various musculoskeletal and skin manifestations are involved. Beyond these features, PsA is associated with comorbidities that might increase the burden of the disease. Areas covered In the last years a growing interest has come out for the concept of multimorbidity in rheumatology. Multimorbidity was defined as the
-
Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-09-29 Virginia Solitano,Ferdinando D'Amico,Gionata Fiorino,Laurent Peyrin-Biroulet,Silvio Danese
ABSTRACT Introduction After patents’ expiration of biological originators, several biosimilars of infliximab and adalimumab have been authorized. The approval is based on data extrapolated from other indications for which the originator has been previously tested. Despite rigorous approval processes by regulatory entities, physicians’ and patients’ knowledge about biosimilars is limited and some concerns
-
Systematic review of the antiviral properties of TRIM56: a potential therapeutic intervention for COVID-19. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-09-29 Fatemeh Heidary,Reza Gharebaghi
ABSTRACT Introduction The tripartite motif (TRIM) plays various roles in pathological and physiological functions, including neurological diseases, genetic disorders, carcinogenesis, innate immune signaling, and antiviral activity. TRIM56 is a cytoplasmic protein whose expression is stimulated by type I interferon and may function as an antiviral agent. Here, the authors conducted a systematic search
-
Dupilumab for the treatment of adolescents with atopic dermatitis. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-13 Sonja Senner,Marlene Seegräber,Surina Frey,Benjamin Kendziora,Laurie Eicher,Andreas Wollenberg
Introduction Dupilumab is a treatment option newly licensed for adolescents with moderate to severe atopic dermatitis (AD). It reduces type 2 inflammation by blocking the shared receptor subunit for IL-4/-13. Dupilumab affects three disease mechanisms in atopic dermatitis: the skin barrier, the Th2-cell differentiation and the class switch to IgE. This report is based on a systematic literature search
-
Expert opinion on the management and follow-up of uveitis patients during SARS-CoV-2 outbreak. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-07-21 Dinu Stanescu-Segall,Thomas Sales de Gauzy,Rhianon Reynolds,Livia Faes,Dominika Pohlmann,Kaivon Pakzad-Vaezi,Daniel Ting,David Saadoun,Jayakrishna Ambati,Anat Loewenstein,Bahram Bodaghi,Marc D de Smet,Sara Touhami
Introduction Routine medical and ophthalmic care is being drastically curtailed in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Uveitis patients require particular attention because of their theoretical risk of viral infection, in the context of therapeutic immunosuppression. Areas covered This collaborative work proposes practical management and follow-up
-
Swinging the pendulum: lessons learned from public discourse concerning hydroxychloroquine and COVID-19. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-11 Sebastian E Sattui,Jean W Liew,Elizabeth R Graef,Ariella Coler-Reilly,Francis Berenbaum,Alí Duarte-García,Carly Harrison,Maximilian F Konig,Peter Korsten,Michael S Putman,Philip C Robinson,Emily Sirotich,Manuel F Ugarte-Gil,Kate Webb,Kristen J Young,Alfred H J Kim,Jeffrey A Sparks
Introduction Several months into the COVID-19 pandemic, safe and effective treatments against this global health disaster have yet to be identified. Clinical research trials around the world are underway testing a wide array of possible medications. In particular, the off-label use of hydroxychloroquine for COVID-19 prophylaxis and treatment has created many unprecedented challenges for the scientific
-
Elimination diets for eosinophilic esophagitis: making the best choice. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-04 Mirna Chehade,Shimron Brown
Introduction Dietary elimination therapy has long been an option for patients with eosinophilic esophagitis (EoE). Multiple diets have been reported, with variable efforts involved, efficacy rates, costs, and long-term management plans. Although the pros and cons of dietary elimination therapy have been described, a clear method for deciding on who is the right candidate for a diet, and which diet
-
Global systematic review of primary immunodeficiency registries. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-09-17 Hassan Abolhassani,Gholamreza Azizi,Laleh Sharifi,Reza Yazdani,Monireh Mohsenzadegan,Samaneh Delavari,Mahsa Sohani,Paniz Shirmast,Zahra Chavoshzadeh,Seyed Alireza Mahdaviani,Arash Kalantari,Marzieh Tavakol,Farahzad Jabbari-Azad,Hamid Ahanchian,Tooba Momen,Roya Sherkat,Mahnaz Sadeghi-Shabestari,Soheila Aleyasin,Hossein Esmaeilzadeh,Waleed Al-Herz,Ahmed Aziz Bousfiha,Antonio Condino-Neto,Mikko Seppänen
Introduction During the last 4 decades, registration of patients with primary immunodeficiencies (PID) has played an essential role in different aspects of these diseases worldwide including epidemiological indexes, policymaking, quality controls of care/life, facilitation of genetic studies and clinical trials as well as improving our understanding about the natural history of the disease and the
-
A new case of congenital ficolin-3 deficiency with primary immunodeficiency. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-08-11 Fateme Babaha,Hassan Abolhassani,Zahra Hamidi Esfahani,Reza Yazdani,Asghar Aghamohammadi
Objectives Human Ficolin-3 (FCN3) is an oligomeric-structured lectin encoded by the FCN3 gene with a pivotal role in the lectin complement pathway. It has anti-microbial activities against bacterial and viral infections and restrains opportunistic pathogens. Mutation in the FCN3 gene is associated with variable clinical manifestations particularly immunologic (infections and autoimmunity) and neurologic
-
Atopic phenotypes and their implication in the atopic march. Expert Rev. Clin. Immunol. (IF 3.792) Pub Date : 2020-09-16 Adnan Custovic,Darije Custovic,Blazenka Kljaić Bukvić,Sara Fontanella,Sadia Haider
ABSTRACT Introduction Eczema, allergic rhinitis, and asthma are traditionally considered atopic (or allergic) diseases. They are complex, multifactorial, and are caused by a variety of different mechanisms, which result in multiple heterogeneous clinical phenotypes. Atopic march is usually interpreted as the sequential development of symptoms from eczema in infancy, to asthma, and then allergic rhinitis